Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077

Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolley, Elizabeth E., Zangeneh, Sahar Z., Chau, Gordon, Eron, Joe, Grinsztejn, Beatriz, Humphries, Hilton, Liu, Albert, Siegel, Marc, Bertha, Maseko, Panchia, Ravindre, Li, Sue, Cottle, Leslie, Rinehart, Alex, Margolis, David, Jennings, Andrea, McCauley, Marybeth, Landovitz, Raphael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423859/
https://www.ncbi.nlm.nih.gov/pubmed/32052214
http://dx.doi.org/10.1007/s10461-020-02808-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423859/
https://www.ncbi.nlm.nih.gov/pubmed/32052214
http://dx.doi.org/10.1007/s10461-020-02808-2

Ejemplares similares